Research Paper Volume 16, Issue 22 pp 13608—13626
Unveiling KLHL23 as a key immune regulator in hepatocellular carcinoma through integrated analysis
Figure 7. The functional role of KLHL23 in LIHC. (A) Differences in the immune cell signaling pathway in different proportions of immune cells between groups with high and low KLHL23 expression in LIHC. (Abbreviation: ns: no significant difference. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). (B) Single cell analysis of KLHL23 expression in different cell types. (C–F) Analysis of drug sensitivity based on KLHL23 expression in LIHC. (C) Sorafenib, (D) Gemcitabine, (E) Vorinostat, and (F) Doxorubicin. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).